Zhaoke Ophthalmology Limited (HKG:6622)

Market Cap	1.85B +111.3%
Revenue (ttm)	38.74M -38.2%
Net Income	-304.97M
EPS	-0.56
Shares Out	547.97M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,838,500
Average Volume	596,105
Open	3.100
Previous Close	3.110
Day's Range	3.090 - 3.460
52-Week Range	1.300 - 4.600
Beta	1.21
RSI	51.92
Earnings Date	Mar 24, 2026

About Zhaoke Ophthalmology

Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, Hong Kong, and internationally. It develops various drugs that cover ophthalmic indications, including dry eye disease, myopia, presbyopia, wet age-related macular degeneration, diabetic macular edema, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 270
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6622

Financial Performance

In 2024, Zhaoke Ophthalmology's revenue was 69.32 million, an increase of 269.73% compared to the previous year's 18.75 million. Losses were -237.49 million, -38.32% less than in 2023.

Financial numbers in CNY